A Phase 1, Parallel, Randomized Trial To Assess The Effect Of Time Of Dosing On The Pharmacodynamics, Pharmacokinetics, Safety And Tolerability Of Multiple Oral Doses Of PF-04620110 In Otherwise Healthy Overweight Or Obese Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2011
At a glance
- Drugs PF 4620110 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 18 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2011 Additional trial locations (Belgium, Singapore) identified as reported by ClinicalTrials.gov.
- 16 Mar 2011 Planned end date changed from 1 Oct 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.